Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium
A scientific symposium was held on the 24th May 2019, which aimed to share the advance of stroke rehabilitation and the role of NeuroAiD in post-stroke recovery.
Clinicians from Southeast Asia, Europe, and Middle-East attended the symposium. International faculties presented their perspectives on patients’ journey through stroke recovery and the critical role of both rehabilitation and NeuroAiD to achieve functional independence.
- Professor Christopher Chen from the National University of Singapore provided an overall perspective and moderated the entire scientific session
- Professor Pamela Duncan from Wake Forest University of the United States of America, presented stroke recovery therapeutics and rehabilitation
- Professor NV Ramani from Raffles Hospital Singapore, presented the effects of NeuroAiD on long-term functional outcomes after stroke
- Professor Suwanwela NC from Chulalongkorn University Thailand, presented the effects of combination treatment with NeuroAiD and rehabilitation
- Professor M Lazdunski from CNRS France, presented NeuroAiD’s multimodal mode of action
Professor Duncan emphasized that “we are transforming acute care”. Indeed, the mortality rate of stroke patients in the United States is decreasing, however, “we are not managing the disability” among these patients. In other words, “stroke patients are living longer, with higher chance of survival, but they are not given with optimal recovery”. It is important to note that in “rehab and recovery, there is reorganization of the brain, neurogenesis, regulation of growth factors, and all of these processes take time. Therefore the “primary endpoint of clinical trials assessing recovery should be 6 months to 1 year”, she added.
CHIMES-E, NeuroAiD’s landmark study, assessed recovery for up to 2 years following a stroke. More patients in the treatment group achieved functional independence (mRS 0-1) with significant results from month 6 to 18 compared to the placebo group. Moreover, combining NeuroAiD and rehabilitation doubled the odds of achieving functional independence as early as month-3, with effect persisting over 2 years as compared to patients who underwent rehabilitation alone.
NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.
Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.